Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

Phase I Dose Escalation Study of 3-Weekly Intravenous DPPG2-TSL-DOX Combined With Regional Hyperthermia in Locally Advanced or Metastatic Soft Tissue Sarcoma

This study aims to explore a new therapeutic approach for advanced soft tissue sarcoma (STS) by investigating the safety, tolerability, and maximum tolerated dose (MTD)/highest tolerated dose (HTD) of DPPG2-TSL-DOX combined with regional hyperthermia (RHT) in patients who have been pre-treated with anthracycline, e.g. doxorubicin (DOX).

Study Overview

• Status: Completed
• Conditions: Sarcoma, Soft Tissue
• Intervention / Treatment: Drug: DPPG2-TSL-DOX; Drug: Dexrazoxane

Detailed Description

Considering that up to 40 percentage of patients with soft tissue sarcoma (STS) will develop metastatic disease and that for these patients overall survival (OS) ranges between 3.7 to 25 months it becomes clear that new therapeutic approaches for the treatment of advanced STS are urgently needed. Doxorubicin (DOX) is a cytotoxic compound that belongs to the class of anthracyclines. DOX has had market authorization since 1960s and is considered the most active chemotherapeutic drug for the treatment of STS. DPPG2-TSL-DOX is a novel formulation of DOX encapsulated in DPPG2-containing thermosensitive liposomes (TSL). Regional hyperthermia (RHT) with a tumor target temperature of ≥41.5 to ≤44 degree of Celsius combined with anthracycline-based chemotherapy has shown to improve survival in patients with localized high-risk STS. Treatment with DPPG2-TSL-DOX aims at combining the confirmed anti-tumor efficacy of anthracyclines in the treatment of locally advanced STS with RHT-triggered DOX release from circulating liposomes resulting in higher local DOX concentrations in the tumor as observed in preclinical studies.

DPPG2-TSL-DOX combined with RHT has been investigated in feline sarcoma at 1 mg/kg dose level resembling the clinically recommended dose level of standard DOX with considerably improved efficacy and better tolerability. The proposed study will characterize the safety and tolerability and, if applicable, the maximum tolerated dose (MTD)/highest tolerated dose (HTD) of DPPG2-TSL-DOX in combination with RHT in patients with advanced or metastatic STS who have been pre-treated with anthracycline. An adapted 3+3 MAD study design with sentinel dosing and a starting dose of 20 mg/m^2 DPPG2-TSL-DOX is applied in this study to identify dose-limiting toxicities (DLTs) of DPPG2-TSL-DOX in combination with RHT.

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 13125
    • Helios Klinikum Berlin-Buch GmbH
  • Munich, Germany, 81377
    • Klinikum der Universität München (KUM) Campus Großhadern

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria

1. Age at the time of consent ≥18 years.
2. Patient has provided written informed consent prior to any study-specific procedure.
3. Locally advanced (unresectable) or metastatic STS, including histological sarcoma subtypes treated as STS, for which treatment with DOX monotherapy is appropriate, as confirmed by the investigator.
4. Pretreatment with an anthracycline (including DOX, epirubicin as mono- or combination therapy). Patients who received anthracycline in an adjuvant setting are eligible.

5. Progressive disease not suitable for surgery after

   1. only one further line of chemotherapy (including TKI) if the RHT field targets the clinically relevant tumor manifestation/s (e.g., locally advanced or multifocal intraabdominal STS; diffuse metastatic STS in which RHT of a tumor manifestation [e.g., liver] is considered relevant although other systemic metastases are present that do not endanger the patient, as per the judgment of the investigator), or
   2. two or more further lines of chemotherapies (including TKI) for patients with metastatic STS and a tumor manifestation suitable for RHT.
6. All previous oncological treatments must have been completed ≥3 weeks (21 days) prior to the first dose of study treatment, ensuring a sufficient washout period.
7. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer et al. 2009).
8. Tumor accessible for RHT.
9. Left ventricular ejection fraction (LVEF) >50% (within 28 days prior to enrolment).

10. Adequate hematologic, organ and coagulation function within 14 days prior to enrolment as assessed by local lab:

    1. Absolute neutrophil count (ANC) ≥1.5×10^9/L. Granulocyte-colony stimulating factor (G-CSF) cannot be administered within 2 weeks (14 days) prior to enrolment.
    2. Platelet count ≥100×10^9/L.
    3. Hemoglobin ≥9.0 g/dL. No transfusions are allowed within 2 weeks (14 days) prior to enrolment.
    4. Serum creatinine ≤1.5 times upper limit of normal (ULN).
    5. Negative dipstick for proteinuria or if proteinuria ≥2+ (equals ≥ 1001 mg/L or 1.001 g/L (Lamb, et al., 2009), then additional 24 h urine collection <1g protein/ 24 h.
    6. Total bilirubin within ULN (except for patients with Gilbert's syndrome, who must have a total bilirubin <3 mg/dL).
    7. ALT/ AST ≤3.0×ULN; if the liver has tumor involvement, AST and ALT ≤5.0×ULN are acceptable.
    8. An adequate coagulation function as defined by international normalized ratio (INR) ≤1.5×ULN or prothrombin time ≤1.5×ULN, and partial thromboplastin time ≤1.5×ULN (unless receiving anticoagulant therapy). Patients receiving phenprocoumon are recommended to switch to low molecular weight heparin and should have achieved stable coagulation status prior to the first dose of study treatment.
11. Tubular excretion rate (TER) by MAG-3-clearance ≥ TERLoLi (TERLoLi = 70% TERNorm).
12. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Appendix 1).

13. If female, must:

    1. Be not of child-bearing potential due to surgical sterilization (at least 6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) confirmed by medical history or menopause.
    2. Be a post-menopausal woman, defined as a woman meeting either of the following criteria:

    i. spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (for example, oral contraceptives, hormones, gonadotropin-releasing hormone, antiestrogens, selective estrogen receptor modulators [SERMs], or chemotherapy) ii. spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone level >40 mIU/mL.

14. Women of childbearing potential (WOCBP; for a definition see Appendix 2) and men able to father a child must be ready and able to use two medically acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at screening, during trial participation, and until 6 months after last dose of study treatment. Also, partner of male participants, who is of childbearing potential must use a highly effective method of contraception during the same duration (Please refer to Appendix 2 for methods of highly effective contraception). A list of contraception methods meeting these criteria is provided in the patient information.
15. At least 3 months' life expectancy in the investigator's assessment.

Exclusion criteria

1. Patients already enrolled in any clinical study involving an investigational product or medical device or have participated within the past 30 days in a clinical trial involving an investigational product or medical device.

2. History of another primary malignancy, with the exception of:

   1. curatively treated non-melanomatous skin cancer
   2. curatively treated cervical carcinoma in situ
   3. non-metastatic prostate cancer, or
   4. other primary non-hematologic malignancies that had been treated with curative intent, no known active disease, and no treatment administered during the last 3 years prior to enrolment that the investigator agrees will not affect the interpretation of study results or would be unsuitable for participation in the study.
3. Active fungal, bacterial and/or known viral infection including human immunodeficiency virus or viral (A, B, or C) hepatitis.
4. Resting heart rate of >100 bpm (measured after ≥10 min. in seated position). Note: If >100 bpm, the measurement should be repeated by up to 3 consecutive measurements at least 10 minutes apart from each other. If all 3 measurements are >100 bpm the exclusion criterion is met.
5. Uncontrolled intercurrent illness including, but not limited to, an ongoing/active infection requiring parenteral antibiotics.

6. Have a serious cardiac condition, such as:

   1. unstable angina pectoris
   2. angioplasty, cardiac stenting, or myocardial infarction within 6 months of enrolment
   3. valvulopathy that is severe, moderate, or deemed clinically significant
   4. arrhythmias that are symptomatic or require treatment
7. Have a QTcF interval of >450 msec for males and >470 msec for females on screening electrocardiogram (ECG) utilizing Fridericia's correction.
8. Psychiatric illness or social situation that would limit compliance with study requirements.
9. Any planned or required major surgery during the course of the study.
10. Pregnant or breastfeeding female.
11. Individuals who are institutionalized on a judicial or regulatory order.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: IV DPPG2-TSL-DOX; DPPG2-TSL-DOX (20 or 40 or 50 mg/m^2) + regional hyperthermia (RHT) 3 dose levels are planned in this study: dose level 1 will be receiving 20 mg/m^2 DPPG2-TSL-DOX, dose level 2 will be receiving 40 mg/m^2 DPPG2-TSL-DOX, dose level 3 will be receiving 50 mg/m^2 DPPG2-TSL-DOX. Participants are to be treated with DPPG2-TSL-DOX infusion over 30 minutes and RHT every three weeks (one cycle = 21 days), receiving up to 6 cycles in Main Study Phase and additional 6 cycles in Treatment Continuation Phase, if eligible: In the first cycle (cycle 1), DPPG2-TSL-DOX application will be performed without RHT in all participants for safety precaution.; In cycles 2-12, DPPG2-TSL-DOX will be applied in parallel with RHT. Dexrazoxane as cardioprotectant will be provided for participants overcoming a cumulative dose of 300 mg/m^2 DOX.

Drug: DPPG2-TSL-DOX; DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.; Other Names: Doxorubicin; THE001; Drug: Dexrazoxane; For cardioprotection of participants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD)	If no more than 1 subject experiencing DLTs is identified after all subjects completed cycle 3 in dose level 3, MTD for the current study and study population will be considered 50 mg/m2.	End of study (up to 14 months)
Highest tolerated dose (HTD)	Highest dose considered safe for dose escalation by the independent DSMB in the FiH study provided < 33% experiencing a DLT per DL are reported in the study until completion or early termination.	End of study (up to 14 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AEs)	Number of treatment-emergent AEs according to CTCAE 5.0	End of study (up to 14 months)
Serious Adverse Events (SAEs)	Number of treatment-emergent SAEs according to CTCAE 5.0	End of study (up to 14 months)
Laboratory abnormalities	Number of laboratory abnormalities	End of study (up to 14 months)
Electrocardiogram (ECG) abnormalities	Number of participants with ECG abnormalities	End of study (up to 14 months)
Echocardiogram (ECHO) abnormalities	Number of participants with ECHO abnormalities	End of study (up to 14 months)
Renal toxicities	Number of participants with renal toxicities	End of study (up to 14 months)
Maximum concentration (Cmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Last measurable (non-zero) concentration (Clast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Area under the curve from time 0 to x hours (AUC[0-x] ) after the start of infusion of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Area under the curve from time 0 to the time of the last quantifiable concentration (AUC[0-tlast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Time of maximum observed concentration (Tmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Terminal half-life (T½) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Clearance (CL) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Volume of distribution at steady-state (Vss) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	without RHT (cycle 1; 12 time points)	End of study (upto 14 months)
Maximum concentration obtained after administration (Cmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)
Last measurable (non-zero) concentration (Clast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)
Area under the curve from time 0 to x hours (AUC[0-x] ) after the start of infusion of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)
Area under the curve from time 0 to the time of the last quantifiable concentration (AUC[0-tlast) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)
Time of maximum observed concentration (Tmax) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)
Terminal half-life (T½) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)
Clearance (CL) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)
Volume of distribution at steady-state (Vss) of DPPG2, non-liposomal DOX, liposomal encapsulated DOX and total DOX	with RHT (cycle 2; 12 time points)	End of study (upto 14 months)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Radiographic response	Radiographic response rates (CR, PR, SD, PD) and ORR (CR+PR) as assessed by RECIST 1.1	day 64 (+/-3) in the study for each participant and end of study (21 [+7] days after last study drug treatment)
Radiographic local response	Radiographic local response rates (CR, PR, SD, PD) by Choi et al. 2007 assessed for target and non-target lesions in RHT field	day 64 (+/-3) in the study for each participant and end of study (21 [+7] days after last study drug treatment)
Tumor temperatures (optional)	Specific tumor temperature parameters: Tmax, T90, T50, T20 and respective cumulative minutes	day 23, 44, 65, 86, 107 (+/-3) in the study for each participant

Collaborators and Investigators

• Sponsor: Thermosome GmbH
• Investigators: Principal Investigator: Peter Reichardt, PD Dr., Helios Klinikum Berlin-Buch GmbH

Publications and helpful links

Helpful Links

• Sponsor's website giving information on the drug technology

Study record dates

Study Major Dates

• Study Start (Actual): April 19, 2023
• Primary Completion (Actual): January 30, 2025
• Study Completion (Actual): May 28, 2025

Study Registration Dates

• First Submitted: April 24, 2023
• First Submitted That Met QC Criteria: May 12, 2023
• First Posted (Actual): May 15, 2023

Study Record Updates

• Last Update Posted (Actual): July 28, 2025
• Last Update Submitted That Met QC Criteria: July 23, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: Sarcoma, Soft Tissue; Doxorubicin; Doxorubicin/ IV + Liposomes
• Additional Relevant MeSH Terms: Wounds and Injuries; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Connective and Soft Tissue; Body Temperature Changes; Heat Stress Disorders; Hyperthermia; Sarcoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimitotic Agents; Mitosis Modulators; Topoisomerase Inhibitors; Topoisomerase II Inhibitors; Protective Agents; Cardiotonic Agents; Doxorubicin; Dexrazoxane; Razoxane
• Other Study ID Numbers: TS-DM-STS-101; 2020-005033-32 (EudraCT Number); 2023-507836-19-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No